Michael Valitutto, DO
Internal Medicine · Kalamazoo, MINPI 1326074378
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $1,421,755 of the $1,751,968 with a category attached, or 81.2%. 34 manufacturers reported payments, led by Lilly USA, LLC at 33.6% of the total. Among internal medicine clinicians in MI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 3,380 payments — averaging $518.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$589K
- Novo Nordisk$360K
- Corcept Therapeutics$233K
- Bayer$182K
- AstraZeneca$99K
- Boehringer Ingelheim$71K
- plus $218K from 28 others
What the payments were for
- Consulting fees$50,8793%
- Speaking & faculty fees$1,421,75581%
- Travel & lodging$228,21313%
- Food & beverage$50,7793%
- Education$2830%
- Gifts$590%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 997 | $589,191 |
| Novo Nordisk | 696 | $359,684 |
| Corcept Therapeutics | 278 | $232,770 |
| Bayer | 240 | $182,405 |
| AstraZeneca(2 entities) | 110 | $98,781 |
| Boehringer Ingelheim | 179 | $70,704 |
| Insulet Corporation | 264 | $56,241 |
| Amgen(2 entities) | 108 | $40,984 |
| Sanofi-aventis U.S. LLC | 34 | $23,435 |
| Abbott | 60 | $23,069 |
| Cequr Corporation | 6 | $20,093 |
| GSK | 1 | $12,350 |
| AbbVie | 18 | $10,472 |
| Dexcom, Inc. | 79 | $8,795 |
| Valeritas, Inc. | 45 | $7,417 |
| Madrigal Pharmaceuticals | 24 | $5,346 |
| Mannkind Corporation | 61 | $4,606 |
| Zealand Pharma US, Inc. | 10 | $2,179 |
| Tandem Diabetes Care, Inc. | 55 | $1,073 |
| Regeneron Healthcare Solutions, Inc. | 2 | $648 |
| Novartis | 53 | $590 |
| Johnson & Johnson | 37 | $499 |
| Medtronic(2 entities) | 4 | $180 |
| Ascensia Diabetes Care US Inc. | 1 | $98 |
| Neurocrine Biosciences, Inc. | 3 | $83 |
| Companion Medical, Inc. | 4 | $80 |
| Senseonics, Incorporated | 2 | $51 |
| Tolmar, Inc. | 2 | $37 |
| Merck | 2 | $31 |
| Aimmune Therapeutics, Inc. | 1 | $23 |
| Sequel Med Tech, LLC | 1 | $17 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $13 |
| Pfizer | 1 | $12 |
| Xeris Pharmaceuticals, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Korlym$228,969
- TRULICITY$214,909
- JARDIANCE$204,715
- Kerendia$180,066
- MOUNJARO$160,956
- Ozempic$143,321
- FARXIGA$84,430
- RYBELSUS$83,267
- Wegovy$60,563
- Omnipod$52,702
- Saxenda$45,340
- TEPEZZA$37,940
- CeQur Simplicity$20,093
- HUMULIN$18,075
- PRALUENT$12,803
- FreeStyle Libre Pro$12,463
- V-GO$11,192
- FREESTYLE LIBRE 3$9,214
- SOLIQUA 100/33$6,683
- Tresiba$5,543
How this compares
$1,751,968 in reported general payments places this provider in the 95th percentile of 4,567 internal medicine providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| KorlymMifepristone | 58 | $2,004,577 |
| OzempicSemaglutide | 902 | $1,353,490 |
| JardianceEmpagliflozin | 673 | $726,035 |
| TrulicityDulaglutide | 504 | $696,296 |
| MounjaroTirzepatide | 444 | $630,039 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 251 | $396,436 |
| FarxigaDapagliflozin Propanediol | 353 | $341,259 |
| Omnipod Dash Pods (Gen 4)Insulin Pump Cart,cont Inf,bt | 169 | $221,843 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 97 | $134,970 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 35 | $130,143 |
| Humulin R U-500Insulin Regular, Human | 50 | $121,808 |
| NovologInsulin Aspart | 289 | $115,468 |
| V-Go 40Sub-Q Insulin Device, 40 Unit | 179 | $113,881 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 134 | $95,273 |
| Bydureon BciseExenatide Microspheres | 50 | $92,469 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Corcept TherapeuticsKorlym | $232,770 | $2,004,57758 claims |
| Novo NordiskOzempic, Novolog, Fiasp, Rybelsus | $359,684 | $1,601,9581,268 claims |
| Lilly USA, LLCTrulicity, Mounjaro, Humalog, Lyumjev, Baqsimi | $589,191 | $1,478,4161,296 claims |
| Boehringer IngelheimJardiance, Tradjenta | $70,704 | $754,333698 claims |
| AstraZenecaFarxiga | $98,781 | $341,259353 claims |
| AbbVieCreon | $10,472 | $89,74614 claims |
| BayerKerendia | $182,405 | $74,67470 claims |
| Johnson & JohnsonInvokana | $499 | $34,31121 claims |
| MerckJanuvia | $31 | $34,07128 claims |
| AmgenProlia | $40,984 | $24,13514 claims |
| PfizerEliquis | $12 | $23,37715 claims |
| Cequr CorporationCequr Simplicity | $20,093 | $23,21742 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,567 internal medicine providers in Michigan.
Other internal medicine in Kalamazoo
- Terry SmithAnn Arbor$2.3M
- Ulka VaishampayanAnn Arbor$996K
- Tina AbrahamPontiac$834K
- Steven KatzmanLivonia$715K
- Adam FormanSouthfield$453K
- Saroj NeupaneDetroit$373K
- James BazziDearborn Heights$368K
- Mohamad HatahetWaterford$352K
- A FendrickAnn Arbor$347K
- David StocktonDetroit$306K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.